Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Campone

Showing results (261-270 of 302) with videos related to

Pageof 31
Sort By:
Breast (Edinburgh, Scotland)|May 8, 2020
Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohortSophie Frank, Matthieu Carton, Coraline Dubot, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 3, 2020
Cognitive Impairment in Patients with Breast Cancer before Surgery: Results from a CANTO Cohort SubgroupMarie Lange, Isabelle Hardy-Léger, Idlir Licaj, et al.
Breast Cancer Research and Treatment|March 7, 2024
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trialAngeline Ginzac, Ioana Molnar, Xavier Durando, et al.
Ebiomedicine|May 8, 2024
Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trialSylvie Giacchetti, Enora Laas, Thomas Bachelot, et al.
European Journal of Cancer (Oxford, England : 1990)|September 22, 2018
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2Mario Campone, Seock-Ah Im, Hiroji Iwata, et al.
Neurology|May 12, 2019
Imaging necrosis during treatment is associated with worse survival in EORTC 26101 studyMartha Nowosielski, Thierry Gorlia, Jacoline E C Bromberg, et al.
Current Medical Research and Opinion|August 22, 2013
Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapyMario Campone, J Thaddeus Beck, Michael Gnant, et al.
JCO Precision Oncology|September 11, 2020
Exploitation of Precision Medicine Trials Data: Examples of Long Responders From the SHIVA01 TrialClémence Basse, Claire Morel, Céline Callens, et al.
Annals of Surgery|February 3, 2021
Early Locoregional Breast Surgery and Survival in de novo Metastatic Breast Cancer in the Multicenter National ESME CohortJudicaël Hotton, Amélie Lusque, Léa Leufflen, et al.
The New England Journal of Medicine|November 16, 2017
Lomustine and Bevacizumab in Progressive GlioblastomaWolfgang Wick, Thierry Gorlia, Martin Bendszus, et al.
Pageof 31

Showing results (261-270 of 302) with videos related to

Sort By:
Pageof 31
Breast (Edinburgh, Scotland)|May 8, 2020
Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohortSophie Frank, Matthieu Carton, Coraline Dubot, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 3, 2020
Cognitive Impairment in Patients with Breast Cancer before Surgery: Results from a CANTO Cohort SubgroupMarie Lange, Isabelle Hardy-Léger, Idlir Licaj, et al.
Breast Cancer Research and Treatment|March 7, 2024
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trialAngeline Ginzac, Ioana Molnar, Xavier Durando, et al.
Ebiomedicine|May 8, 2024
Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trialSylvie Giacchetti, Enora Laas, Thomas Bachelot, et al.
European Journal of Cancer (Oxford, England : 1990)|September 22, 2018
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2Mario Campone, Seock-Ah Im, Hiroji Iwata, et al.
Neurology|May 12, 2019
Imaging necrosis during treatment is associated with worse survival in EORTC 26101 studyMartha Nowosielski, Thierry Gorlia, Jacoline E C Bromberg, et al.
Current Medical Research and Opinion|August 22, 2013
Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapyMario Campone, J Thaddeus Beck, Michael Gnant, et al.
JCO Precision Oncology|September 11, 2020
Exploitation of Precision Medicine Trials Data: Examples of Long Responders From the SHIVA01 TrialClémence Basse, Claire Morel, Céline Callens, et al.
Annals of Surgery|February 3, 2021
Early Locoregional Breast Surgery and Survival in de novo Metastatic Breast Cancer in the Multicenter National ESME CohortJudicaël Hotton, Amélie Lusque, Léa Leufflen, et al.
The New England Journal of Medicine|November 16, 2017
Lomustine and Bevacizumab in Progressive GlioblastomaWolfgang Wick, Thierry Gorlia, Martin Bendszus, et al.
Pageof 31